Global EditionASIA 中文雙語Fran?ais
Opinion
Home / Opinion / Opinion Line

Domestic COVID-19 drug raises hopes

China Daily | Updated: 2022-08-16 07:45
Share
Share - WeChat

The National Healthcare Security Administration has announced that all the medicines listed in the COVID-19 treatment plan can be paid for through the healthcare security fund.

On Aug 9, the National Health Commission said that Azvudine, a Chinese drug approved for treating COVID-19, was included in the COVID-19 treatment plan. This way, patients can get part of the cost paid for by the healthcare security fund.

A worker carries out sample testing in a medical company in Jiangsu province, on April 9, 2020. [Photo by Tang Dehong/for China Daily]

Society has long been expecting COVID-19 drugs to enter the market. China has long developed vaccines aimed at preventing the virus from infecting more people. The emerging drugs will further consolidate China's victory over the virus.

Azvudine, as the first domestically developed COVID-19 drug, has several advantages over foreign ones. It costs less than 300 yuan ($44.35) per bottle, which is largely affordable; it is an oral drug rather than injection, which makes it convenient to popularize it.

Besides, since Azvudine has long been used to fight AIDS and has recently been developed to fight COVID-19, its side-effects are known.

However, some believe that more clinical data is needed to prove its effectiveness. After all, Azvudine has not been tested yet for its effectiveness against COVID-19. That's possibly why the medicine has been "temporarily" included in the healthcare fund, creating room for a long-term decision to be taken after observation. In that way, the taxpayers' burden will not be that heavy.

More than two years into the COVID-19 pandemic, people are looking for an effective, cheap drug to counter it.

With the first domestically developed COVID-19 drug entering the market and getting included in the healthcare fund, there is more light at the end of the tunnel. Of course, one single drug is far from enough in fighting the pandemic, yet it highlights the spirit of doing scientific research for fighting the pandemic.

We look forward to more such drugs being developed to better serve the people in the fight against the pandemic.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 性感美女一级毛片| 欧美黑人xxxx性高清版| 国产桃色无码视频在线观看| 一本久久精品一区二区| 日韩美女专区中文字幕| 亚洲色精品vr一区二区三区| 能播放18xxx18女同| 国产特级毛片aaaaaaa高清| aaa一级黄色片| 成年人性生活免费视频| 亚洲av无码片在线观看| 清纯校花被色老头糟蹋| 嗯~啊~哦~别~别停~啊老师| 国产精品入口在线看麻豆| 国自产偷精品不卡在线| 东北女人下面痒大叫| 日韩人妻无码精品无码中文字幕| 亚洲日本视频在线观看| 看全色黄大色黄女片爽毛片| 国产一区二区三区福利| 韩国美女vip福利一区| 国产资源免费观看| 一区二区三区四区精品| 日本一区二区三区四区| 亚洲av无码不卡一区二区三区| 波多野吉衣AV无码| 免费黄色软件下载| 色天天综合色天天害人害己| 国产日本在线观看| 4408私人影院| 大肉大捧一进一出小视频| 三级在线看中文字幕完整版| 日本在线视频www色| 亚洲av无码之日韩精品| 欧美特黄录像播放| 人妻少妇精品视频一区二区三区 | 蜜中蜜3在线观看视频| 国产真实系列在线| 91制片厂天美传媒鲸鱼传媒 | 亚洲欧美日韩精品久久亚洲区| 粗大的内捧猛烈进出视频|